Succinate-CoA Ligase as A Potential Drug Target for Metabolic Disorders

Target Name: Succinate-CoA ligase (ADP-forming)

NCBI ID: P13616

Succinate-CoA ligase (ADP-forming)

Succinate-CoA Ligase as A Potential Drug Target for Metabolic Disorders

Succinate-CoA Ligase (ADP-Forming) as a Drug Target or Biomarker: A Potential Target for the Treatment of Metabolic Disorders

Abstract:
Succinate-CoA ligase (ADP-forming) is an enzyme involved in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. This enzyme plays a crucial role in the production of ATP, which is the primary energy source for the cell. Mutations in the succinate-coa ligase gene have been linked to various metabolic disorders, including phenylketonuria, homocystinuria, and mucosal insulin resistance. In this article, we discuss the potential implications of succinate-coa ligase as a drug target or biomarker for the treatment of metabolic disorders.

Introduction:
Succinate-CoA ligase (ADP-forming) is an enzyme involved in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. This enzyme catalyzes the conversion of succinic acid and CoA to CoA, which then enters the TCA cycle to produce ATP and acetyl-CoA. Succinate-CoA ligase is critical for the production of ATP, which is the primary energy source for the cell.

Mutations in succinate-coa ligase gene have been linked to various metabolic disorders, including phenylketonuria, homocystinuria, and mucosal insulin resistance. These mutations have been shown to alter the levels of succinate-coa ligase and affect its function, leading to a disruption of the TCA cycle and an increase in the production of certain metabolites.

Potential Therapeutic Applications:
Succinate-coa ligase (ADP-forming) has been identified as a potential drug target or biomarker for the treatment of metabolic disorders. By inhibiting the activity of succinate-coa ligase, researchers have found that they can reduce the production of certain metabolites that are associated with the development of metabolic disorders.

In addition to its role in the TCA cycle, succinate-coa ligase has also been shown to play a role in the regulation of cellular signaling pathways. For example, succinate-coa ligase has been shown to regulate the activity of the protein kinase kinase( PKC) and the mitochondrial fission yeast protein (Mf).

Furthermore, succinate-coa ligase has also been shown to play a role in the regulation of cellular energy metabolism. For example, succinate-coa ligase has been shown to promote the production of ATP from ADP and Pi.

Drugs that Interfere with Succinate-CoA Ligase:
Succinate-coa ligase is an enzyme that is involved in the production of ATP, which is a critical energy source for the cell. Therefore, drugs that interfere with succinate-coa ligase have the potential to treat metabolic disorders by reducing the production of ATP.

One class of drugs that have been shown to interfere with succinate-coa ligase is the inhibitors of the TCA cycle. These drugs work by inhibiting the activity of the enzyme succinate-coa ligase, which results in a disruption of the TCA cycle and a reduction in ATP production.

Another class of drugs that have been shown to interfere with succinate-coa ligase are the inhibitors of the PKC. These drugs work by inhibiting the activity of the protein kinase kinase (PKC), which is a downstream

Protein Name: Succinate-CoA Ligase (ADP-forming)

The "Succinate-CoA ligase (ADP-forming) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Succinate-CoA ligase (ADP-forming) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets